Zacks Research cut shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday,Zacks.com reports.
A number of other research firms also recently weighed in on COLL. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.
View Our Latest Stock Report on Collegium Pharmaceutical
Collegium Pharmaceutical Trading Up 1.1%
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.49 earnings per share. Analysts expect that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Collegium Pharmaceutical
Hedge funds have recently bought and sold shares of the company. Group One Trading LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $61,000. PNC Financial Services Group Inc. boosted its holdings in Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 318 shares in the last quarter.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Featured Articles
- Five stocks we like better than Collegium Pharmaceutical
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
